Anti-ischemic cardioprotection with trimetazidine
نویسنده
چکیده
Alterations in cardiac metabolism are present in ischemic heart disease and heart failure, suggesting an increased utilization of non carbohydrate substrates for energy production, with a reduction in the efficiency of myocardial oxygen consumption and ischemia-reperfusion damage. A direct approach to the manipulation of cardiac energy metabolism consists in modifying substrate utilization. Trimetazidine is a pharmacological agent shifting the energy substrate preference away from fatty acid metabolism and towards glucose metabolism. Recent studies suggest that trimetazidine has a positive influence on ischemia-reperfusion damage, endothelial function, and prognosis in patients with coronary artery disease. Heart Metab. 2008;41:25–29.
منابع مشابه
Cardioprotective therapy in reperfusion injury: lessons from the European Myocardial Infarction Project – Free Radicals (EMIP-FR)
Early and successful myocardial reperfusion improves clinical outcomes of patients presenting with acute myocardial infarction (AMI). However, reperfusion itself can exacerbate myocardial injury beyond that caused by ischemia. The European Myocardial Infarction Project – Free Radicals trial (EMIP-FR) was one of the first studies that tested the hypothesis that a cardioprotective agent, such as ...
متن کاملQuality of life with trimetazidine
Trimetazidine, a metabolic agent with anti-ischemic properties, has strong evidence of efficacy and tolerability in the treatment of patients with ischemic cardiomyopathy, including subjects with chronic angina and heart failure. There is now a growing evidence that trimetazidine has also a positive impact on quality of life of these patients. This seems to be a consequence of the clinical bene...
متن کاملThe effect of trimetazidine added to maximal anti-ischemic therapy in patients with advanced coronary artery disease.
BACKGROUND The purpose of the study was to assess the effect of trimetazidine administered for 20 days in 56 patients with ischemic heart disease treated with maximal tolerated doses of anti-ischemic drugs who were not candidates for percutaneous or surgical revascularization. METHODS The efficacy of trimetazidine was evaluated by comparing exercise testing parameters before and after treatme...
متن کاملVastarel MR: from decades of clinical experience in stable angina to new perspectives
Trimetazidine has been known for years as being an effective, ‘‘patient-friendly’’, anti-anginal agent. Recent studies using the modified release formulation (Vastarel MR) have confirmed the efficacy of trimetazidine in stable ischemic heart disease and suggested that it can be beneficial in a number of
متن کاملThe improvement of trimetazidine on exercise performance in ischemic heart disease
Ischemic heart disease (IHD) patients with a decreased exercise capacity have increased angina attack rate and poor quality of life (QOL). Conventional hemodynamic drugs show limited improvement in exercise performance. Therefore we need new drugs that may further improve exercise capacity. Trimetazidine (TMZ) exerts its anti-ischemic effect by reducing fatty acid oxidation and stimulating gluc...
متن کامل